Primary CNS-Lymphoma are a rare but severe disease, which needs an intensive therapy. Although much is known about effective therapies, no standard is established in germany and multiple protocols are in use. The only clear evidence is shown for high-dose-methorexat-poly-chemotherapy, but less is known about ideal dose, duration of therapy or which other chemotherapeutics should be used. The study has no influence on the choice of treatment, this decision is made by the attending physician and the patient.
For this reason all patients over 18 years capable of highdose chemotherapy shall be included. One of the only relevant conditions is an effective immune system. State of the art in current guidelines is a Methotrexat based high-dose chemotherapy.
But due to the high rate of recurrent disease following the high-dose chemotherapy a consolidation therapy is needed. There exist multiple protocols for this. The goal of this registry study is to evaluate these protocols in aduld patients with PCNSL regarding their effectiveness and toxicity. There is no prescribed therapy protocol. The goal ist to evaluate the different protocols of chemotherapy in effectiveness over all survival, progression free survival and tolerance toxicity, therapydiscontinuations.
Lymphoma manifestations outside the CNS, preceding or planned WBRT, previous PCNSL therapy other than corticosteroids, active uncontrolled infection, immunosuppression, concomitant immunsuppressive therapy status post organ Transplantation, HIV infection, concomitant malignancy in the last 5 years other than basal cell carcinoma or carcinoma in situ of the Cervix,.
Organizational Data. Health condition or problem studied. Interventions, Observational Groups. Arm 1: The aim is to enrol patients in fitst-line therapy with PCNSL over the age of 18 years and without contraindications for intensive chemotherapy cf. We would like to document and analyse: demographic information and medical history of the patients e.
